Companies / Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
CompanyMerck Sharp & Dohme LLC is the clinical-trial sponsor entity of Merck & Co., Inc., the American pharmaceutical company headquartered in Rahway, New Jersey. It trades as Merck in the United States and Canada and as MSD in the rest of the world. It is a separate company from Merck KGaA of Darmstadt, Germany, which uses the Merck name outside North America and trades as EMD in the United States and Canada.
- Trials
- 2146
- Recruiting
- 110
- Completed
- 1586
- With results
- 1260
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | Active | Completed | Terminated | Withdrawn | Suspended | Unknown | Approved for marketing | No longer available | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | — | — | — | 1 | — | — | — | — | — | — | 1 |
| Phase 1 | 14 | 6 | 12 | 525 | 70 | 8 | — | — | — | — | 635 |
| Phase 1/2 | 27 | — | 8 | 22 | 9 | 1 | — | — | — | — | 67 |
| Phase 2 | 23 | 4 | 22 | 299 | 93 | 11 | 1 | 3 | — | — | 456 |
| Phase 2/3 | 6 | 1 | — | 13 | 9 | — | — | — | — | — | 29 |
| Phase 3 | 39 | 5 | 53 | 531 | 68 | 16 | — | — | — | — | 712 |
| Phase 4 | — | 2 | — | 72 | 13 | 6 | — | — | — | — | 93 |
| Not applicable | — | — | — | 17 | — | — | — | — | — | — | 17 |
| Unknown | 1 | — | 1 | 106 | 17 | 6 | — | — | 2 | 3 | 136 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Diabetes Mellitus, Type 2 | — | 55 | — | 21 | — | 86 | 6 | 2 | 11 | 181 |
| Parkinson Disease 4, Autosomal Dominant Lewy Body | — | 22 | 18 | 42 | 1 | 91 | 2 | — | 1 | 177 |
| Hepatitis C, Chronic | — | 12 | 5 | 16 | 2 | 31 | 7 | — | 34 | 107 |
| Hepatitis C | — | 28 | 3 | 19 | 3 | 10 | 5 | — | 23 | 91 |
| Carcinoma, Non-Small-Cell Lung | — | 16 | 3 | 21 | 1 | 38 | 1 | — | 1 | 81 |
| HIV Infections | — | 11 | — | 21 | — | 19 | 4 | 7 | 7 | 69 |
| Neoplasms | — | 47 | 6 | 9 | — | 2 | 4 | — | — | 68 |
| Pneumococcal Infections | — | 4 | 2 | 5 | — | 31 | 1 | — | — | 43 |
| Papillomavirus Infections | — | 1 | — | 5 | — | 26 | — | — | 6 | 38 |
| Breast Neoplasms | — | 5 | 2 | 17 | — | 8 | 3 | — | 2 | 37 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | Merck Sharp & Dohme LLC | 2146 | 741 |
Frequent collaborators
| # | Collaborator | Trials |
|---|---|---|
| 1 | Eisai Inc. | 25 |
| 2 | Daiichi Sankyo | 24 |
| 3 | Pfizer | 21 |
| 4 | Ariad Pharmaceuticals | 17 |
| 5 | Centocor, Inc. | 15 |
| 6 | ModernaTX, Inc. | 10 |
| 7 | European Network of Gynaecological Oncological Trial Groups (ENGOT) | 8 |
| 8 | GOG Foundation | 6 |
| 9 | Integrated Therapeutics Group | 6 |
| 10 | Duke Clinical Research Institute | 4 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | pembrolizumab | 265 |
| 2 | peginterferon alfa-2b | 99 |
| 3 | Ribavirin | 97 |
| 4 | Sitagliptin Phosphate | 91 |
| 5 | Carboplatin | 74 |
| 6 | Paclitaxel | 72 |
| 7 | Metformin | 69 |
| 8 | Cisplatin | 66 |
| 9 | Infliximab | 46 |
| 10 | lenvatinib | 45 |
Evidence
- Results reported
- 79.4%1260 of 1586 completed
- Published
- 41.9%665 of 1586 completed
- Primary endpoint met
- 69%1694 of 2455 analyses
- Median months to report
- 11
Documents disclosed
Trial profile
- Median enrollment
- 132
- Median duration
- 20.9months
- Countries
- 67
- Study sites
- 37520
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 18
- Phase 1
- 28
- Phase 1/2
- 140
- Phase 2
- 127
- Phase 2/3
- 342
- Phase 3
- 508
- Phase 4
- 101
- Not applicable
- 540
- Unknown
- 451
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | Seoul | South Korea | 218 |
| 2 | Madrid | Spain | 216 |
| 3 | Barcelona | Spain | 202 |
| 4 | Haifa | Israel | 185 |
| 5 | Santiago | Chile | 177 |
| 6 | Ramat Gan | Israel | 173 |
| 7 | London | United Kingdom | 172 |
| 8 | Milan | Italy | 170 |
| 9 | Ankara | Turkey (Türkiye) | 163 |
| 10 | Jerusalem | Israel | 160 |
Terminations
- Terminated
- 279
- Withdrawn
- 48
- Suspended
- 1
- Stopped for recruitment
- 1.8%39 of 2146 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT06829199 Withdrawn | Withdrawn | Since patients were not recruited yet, we would mark this as a Withdrawn status per the NIH definition of that status. Study halted prematurely, prior to enrollment of first participant. | 2031-03-18 |
| NCT06554730 Withdrawn | Withdrawn | Study is registered /active on RWD Catalogues (https://catalogues.ema.europa.eu) - Please refer to EU PAS number: EUPAS108114 | 2030-12-31 |
| NCT06395090 Withdrawn | Withdrawn | development program discontinuation | 2029-06-30 |
| NCT07224477 Withdrawn | Withdrawn | Business Reasons | 2028-04-04 |
| NCT06721156 Terminated | Terminated | Termination Notes: Business reason | 2026-06-05 |
| NCT04949256 Terminated | Terminated | Trial was rendered as cancelled work ongoing in the book of business. | 2026-05-20 |
| NCT04246177 Terminated | Terminated | Business Reasons | 2026-03-26 |
| NCT06295809 Terminated | Terminated | Business reasons | 2026-03-05 |
| NCT03598608 Terminated | Terminated | Business Reason | 2026-01-28 |
| NCT04738487 Terminated | Terminated | Business Reasons | 2026-01-27 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above:
Search all Merck Sharp & Dohme LLC trials on ClinicalTrials.gov →